Google, Apple, and AMD drag the Nasdaq down as Big Tech's market woes continue

Other tech stocks including Amazon and Tesla are also in the red

We may earn a commission from links on this page.
Image for article titled Google, Apple, and AMD drag the Nasdaq down as Big Tech's market woes continue
Photo: Michael M. Santiago (Getty Images)
In This Story

The Nasdaq and other major stock market indexes dipped Wednesday after underwhelming earnings reports from Google parent Alphabet (GOOGL-0.49%) and chipmaker Advanced Micro Devices (AMD+1.15%). Other tech stocks such as Apple (AAPL+1.27%), Amazon (AMZN-0.73%), and Tesla (TSLA-0.03%) were also in the red.

In the afternoon, the tech-heavy Nasdaq was down about 0.05%, while the Dow Jones Industrial Average and S&P 500 added about 0.28% and 0.13%, respectively.

Advertisement

Alphabet and AMD stock falls after missing revenue

Shares of Alphabet (GOOGL-0.49%) fell more than 7% as the tech giant missed Wall Street’s earnings expectations for the fourth quarter despite “robust momentum across the business.” The Google parent reported revenues of $96.5 billion for the fourth quarter — a 12% increase year-over-year. Alphabet reported earnings of $2.15 per share, up 31% from the previous year, and net income of $26.5 billion for the quarter ended in December.

Advertisement

The company was expected to report revenues of $96.7 billion for the fourth quarter of 2024, according to analysts’ estimates compiled by FactSet (FDS-0.72%). Net income was expected at $26.2 billion, while analysts estimated earnings of $2.13 per share.

Shares in chipmaker Advanced Micro Devices (AMD+1.15%) fell 7% after the company’s fourth-quarter data center revenue missed expectations.

Advertisement

Disney is starting to shed streaming subscribers

Disney’s (DIS+0.72%) streaming business once again turned a profit last quarter. But its flagship platform is starting to lose subscribers.

Advertisement

The House of Mouse on Wednesday released its fiscal first-quarter results, with growth being driven primarily by the company’s box office dominance and profit gains in its streaming business. After rising 2.5% in the morning, the company’s shares were down 1.63% in the afternoon.

The Ozempic boom is slowing down

Sales of Novo Nordisk’s (NVO-1.22%) blockbuster weight loss drug Wegovy doubled in the fourth quarter, but the Danish pharmaceutical giant warns that sales growth for all its drugs — including Ozempic — is expected to slow in the coming year.

Advertisement

Wegovy sales skyrocketed 107% to 19.8 billion Danish Krone ($2.8 billion) in the fourth-quarter of 2024, compared with in 9.6 billion Danish Krone ($1.4 billion) during the the same period last year. The drug just beat analysts’ expectations of $2.7 billion, according to a consensus estimate from FactSet.

The company’s stock rose nearly 4.8% in the afternoon.

—Britney Nguyen and Bruce Gil contributed to this article.